Gut Microbiome in Psoriasis is Perturbed Differently During Secukinumab and Ustekinumab Therapy and Associated with Response to Treatment
Journal
Clinical Drug Investigation
Journal Volume
39
Journal Issue
12
Pages
1195-1203
Date Issued
2019
Author(s)
Abstract
Background and Objective: Immunotherapy could change the complex host-microbial interactions. We aimed to investigate the dynamics of gut microbiome in response to secukinumab [an interleukin (IL)-17 inhibitor] and ustekinumab (an IL-12/23 inhibitor) therapy and its association with treatment response in psoriasis. Methods: This observational, longitudinal study collected a total of 114 fecal samples from 12 healthy controls and 34 patients with psoriasis at baseline and 3 and 6?months after secukinumab (n = 24) or ustekinumab treatment (n = 10) and gut microbiomes were investigated using next-generation sequencing targeting 16S ribosomal RNA. Results: Secukinumab treatment causes more profound alterations in gut microbiome, including increases in the relative abundance of phylum Proteobacteria and decreases in Bacteroidetes and Firmicutes, than ustekinumab treatment. The relative abundance of family Pseudomonadaceae, family Enterobacteriaceae and order Pseudomonadales also increased significantly following secukinumab therapy. In contrast, there was no significant change in gut microbiome composition following ustekinumab treatment, and only genus Coprococcus significantly increased after 6?months of ustekinumab therapy. Moreover, we observed significant differences in baseline gut microbiome between responders and non-responders to secukinumab treatment. Conclusion: These results indicate that gut microbiome is altered differently after anti-IL17 and anti-IL12/23 treatment. Secukinumab (anti-IL17) therapy is associated with distinct and more profound gut microbiome shifts than ustekinumab therapy (anti-IL 12/23) in patients with psoriasis. Moreover, gut microbiome would serve as potential biomarkers of response to secukinumab treatment. ? 2019, Springer Nature Switzerland AG.
SDGs
Other Subjects
genomic DNA; RNA 16S; secukinumab; ustekinumab; interleukin 12; interleukin 17; interleukin 23; monoclonal antibody; secukinumab; ustekinumab; Aeromonas; Article; Bacteroidetes; controlled study; Coprococcus; Enterobacteriaceae; Firmicutes; gene sequence; host microbe interaction; human; intestine flora; longitudinal study; major clinical study; next generation sequencing; nonhuman; observational study; priority journal; Proteobacteria; Pseudomonadaceae; Pseudomonadales; psoriasis; Psoriasis Area and Severity Index; psoriatic arthritis; adult; drug effect; female; intestine flora; male; microbiology; middle aged; psoriasis; Adult; Antibodies, Monoclonal, Humanized; Female; Gastrointestinal Microbiome; Humans; Interleukin-12; Interleukin-17; Interleukin-23; Longitudinal Studies; Male; Middle Aged; Psoriasis; Ustekinumab
Publisher
Springer International Publishing
Type
journal article